Myelodysplasia/myeloid leukemia factor 1-interacting protein (MLF1IP) appears to be an erythroid lineage-specific gene in mice; however, its role in normal erythropoiesis and erythropoietic disorders have not yet been elucidated. Here, we found that MLF1IP is abundantly expressed in human erythroid progenitor cells and that MLF1IP-deficiency reduces cell proliferation resulting from cell cycle arrest. Moreover, MLF1IP expression is exclusively elevated in CFU-E cells from polycythemia vera (PV) patients, and MLF1IP transgenic mice develop a PV-like disorder. Further analyses revealed that the erythroid progenitors and early-stage erythroblasts from these transgenic mice expand by up-regulating cyclin D2 and down-regulating p27 and p21. Thus, our data demonstrate that MLF1IP promotes erythroid proliferation and is involved in the pathogenesis of PV, suggesting that it might be a novel molecular target for erythropoietic disorders.
polo-like kinase 1 (Plk1) [1] , which is a key regulator of a broad range of cell cycle events such as mitotic entry, centrosome maturation, spindle assembly, anaphase-promoting complex/cyclosome regulation, and cytokinesis [5] . In the chicken DT40 cell line, the knockout of MLF1IP results in slower growth and apoptosis as a consequence of a prolonged cell cycle, and apparent premature sister chromatid separation as the spindle checkpoint is activated [3] . Similar mitotic defects are also observed in MLF1IP-deficient HeLa cells, which are associated with an impaired kinetochore-microtubule attachment due to the lack of an interaction with Hec1 [4] .
In humans, MLF1IP is highly expressed in the testis, fetal liver, thymus, and bone marrow (BM) cells, as measured by Northern blotting [6] . Furthermore, among mouse BM precursors of each different hierarchy, MLF1IP mRNA is highly expressed in the colony-forming unit-erythroid (CFU-E) cells, which are undergoing rapid proliferation and are actively going through the cell cycle. MLF1IP expression is apparently lower in CFU-granulocytes and macrophages (CFU-GMs) and in mature B cells, and is negligible in other hematopoietic cells [6] . Considering such a lineage-specific expression and the aforementioned effects on cell biological characteristics, we speculate that MLF1IP might possess unclear functions associated with normal erythropoiesis.
Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) that is characterized by an increased production of mature red blood cells independent of normal erythropoietic regulation [7, 8] . The clinical features of PV include high hemoglobin or hematocrit, splenomegaly [9] , subnormal erythropoietin (EPO) levels [10, 11] , endogenous erythroid colony (EEC) formation [12] , and hypercellularity [13] . Currently, gainof-function mutations, including JAK2V617F and JAK2 exon12 mutants, and consequent EPO-independent JAK2/STAT5 signaling activation are believed to be central to the pathogenesis of PV [14, 15] . JAK2V617F is detected in more than 95% of patients diagnosed with PV and is thus one of the two major criteria in PV diagnosis. Analyses of human PV patients have suggested that JAK2V617F amplifies erythroid cells in a two-step process, i.e., the upstream amplification of JAK2V617F heterozygous erythroid progenitor cells and the downstream proliferation of terminal stages of hematopoietic cells by homozygous cells [16] , which is in accordance with mouse studies showing that JAK2V617F amplified both early and late hematopoietic cells and gave them a proliferative advantage through high cell cycling and low apoptosis [17] . Because MLF1IP functions in the cell cycle and displays an erythroid lineage-specific expression pattern, we suspect that the abnormal expression or dysfunction of MLF1IP might affect erythroid proliferation and ultimately contribute to the pathogenesis of PV.
In this study, we report that MLF1IP is abundantly expressed in the actively proliferating CFU-E and burst-forming unit-erythroid (BFU-E) human erythroid progenitor cells by promoting entry into the G2/M phase of the cell cycle. In PV patients, an even higher expression of MLF1IP was exclusively detected in CFU-E cells, and MLF1IP transgenic mice developed PV-like symptoms after the analysis of hematological features, suggesting that MLF1IP is partially involved in the pathogenesis of PV.
Methods

Patients
The diagnosis of patients was based on the World Health Organization criteria. Individual colony-forming units (CFUs) were identified based on morphological features (some were based on the cytospin analysis) and were extracted with a micropipette using sterilized tips under the microscope. All the patient samples were treated in accordance with the Helsinki Declaration.
Plasmid construction, lentivirus production, cell transduction, and cell culture For the shRNA expression against MLF1IP, the two oligonucleotides used were synthesized as follows: sense, GATCCCAGTGCAAGCCTATTGACGTTTCAAGAGA ACGTCAATAGGCTTGCACTTTTTTGGAAA, and antisense, AGCTTTTCCAAAAAAGTGCAAGCCTATTGAC GTTCTCTTGAAACGTCAATAGGCTTGCACTGG. These oligonucleotides were inserted into a psi-LVRU6GP plasmid (GeneCopoeia, Tianjin, China). The lentiviral packaging was performed according to the Lipofectamine3000 (Invitrogen, Carlsbad, CA, USA) protocol with plasmids (pSAX2 and pMD2.G) in 293T cells. K562 cells were infected with the lentivirus-mediated shRNAs in the presence of 6 mgÁmL À1 polybrene (Sigma-Aldrich, St. Louis, MO, USA). The K562 cells were grown in RPMI 1640 (Gibco-BRL Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) at 37°C in a humidified atmosphere with 5% CO 2 .
In the overexpression experiment, the MLF1IP expression vector was constructed by inserting a human MLF1IP cDNA into pSIN-EF2. The lentiviral packaging was performed according to the Lipofectamine3000 (Invitrogen) protocol with plasmids (pSAX2 and pMD2.G 
Generation of transgenic mice and genotype identification
The entire coding region of human MLF1IP was subcloned into the HS21/45-vav vector [18] , which was kindly provided by Dr Jerry M. Adams (Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia). After removing the pIC19H backbone with HindIII, the linearized vector was microinjected into the pronuclei of C57BL/6J fertilized eggs to generate the founder mice. In this study, both homozygous and heterozygous MLF1IP-positive mice from the F1 to F4 generation were examined as the transgenic (Tg) group, and littermate wild-type (WT) mice served as the control group. The genotypes of the transgenic mice were identified by PCR using genomic DNA from the tail with the forward primer GGAAA TGAAGCAAGTGAAATCGAATCTGTA and the reverse primer ATTCTATTCTTTGTTGATGCTCTAGGTGGG. All experimental protocols were approved by the institutional animal ethics committee.
Real-time PCR and western immunoblotting
Bone marrow mononuclear cells (BMNCs) were isolated from the BM aspirates of patients and of mice using a Ficoll (TBD) density centrifugation method, in which RBCs are located at the bottom of the test tube and separated from BMNCs. The total RNA of BMNCs was extracted with TRIzol reagent (Invitrogen) and then reverse transcribed using the Prime-Script RT Reagent Kit (TaKaRa). Absolute quantitative real-time PCR with TaqMan Gene Expression Assays and universal Master Mix (Life Technologies) were used to examine MLF1IP expression in these BMNCs and colonies from patients and healthy donors. We generated the standard curve for both MLF1IP and GAPDH using MLF1IP or GAPDH plasmids with five known concentrations before analyses (Fig. S1 ). The K562 cells and mouse BM cells were analyzed using SYBR Green PCR Master Mix (Life Technologies). The specific primers are shown in Table S1 . For western blotting, the total cells were lysed with SDS and PMSF (Beyotime, Shanghai, China), separated by SDS/PAGE and transferred to a nitrocellulose membrane (Thermo Fisher Scientific). The membranes were probed with the appropriate antibodies (anti-MLF1IP, Abcam, and Novas Biologicals; anti-p27, -p21, -RB, -phospho-RB, -phospho-STAT5, and -phospho-ERK from Cell Signaling Technology; anti-GAPDH from BioWorld), and the protein bands were detected using ECL Reagent (GE Healthcare, Little Chalfon, UK).
Flow cytometry analysis and cell proliferation assays
For the cell cycle analysis, single-cell suspensions of the K562 cells and the mouse BM cells were permeabilized with 75% ethanol overnight at 4°C, stained with a mix of propidium iodide (PI) and RNAse (Beyotime) for 10 min and analyzed using a BD LSRII flow cytometer. The mouse BM cells were labeled with FITC-anti-CD71 and PE-Cy7-anti-Ter119 (eBioscience, San Diego, CA, USA) to assess the erythroblast populations. Antibodies targeting Lin-APC-Cy7 (a primary antibody, Lineage Cell Detection Cocktail-Biotin, MiltenyiBiotec; secondary antibody, Streptavidin-APC-Cy7, eBioscience), Sca1-PE-Cy7, c-Kit-APC, CD16/32-PE, and CD34-FITC (eBioscience) were used to examine the murine hematopoietic cells.
CCK-8 assay: The cells were seeded at a density of 1000 cells per well in a 96-well plate and were incubated in triplicate. An aliquot of 10 mL of Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) was added to each well, and the mixture was incubated for 6 h. The absorbance was measured at 450 nm to calculate the number of viable cells in each well.
Colony-forming assays were performed in a 24-well plate with semisolid methylcellulose medium (Stemcell, Vancouver, Canada) according to the manufacturer's protocol. K562 cells (1 9 10 3 cells per well, in triplicate) were cultured in H4230 supplemented with 10% FBS, and the colonies were counted on day 14. BMNCs (1 9 10 5 cells per well, in duplicate) from patients were cultured with H4434 (with complete cytokines) and H4534 (without EPO), and the CFUs were harvested on days 7 and 14. For the mouse colony assay, BM cells were cultured in MethoCult TM M3434 and M3334, and the CFUs and BFU-E were harvested on days 3-14.
Blood and tissue analyses in the mice
Mouse peripheral blood samples were collected by tail bleeding into tubes containing the potassium salt of ethylenediaminetetraacetic acid and were analyzed using an XT-2000i Automated Hematology Analyzer (Sysmex, Kobe, Japan). The plasma EPO levels were measured using a Mouse Erythropoietin Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA).
Statistical analysis
The results are presented as the mean AE standard error of mean (SEM). The data were analyzed using a two-tailed Student's t-test. Statistical analyses were performed using GRAPHPAD PRISM software (GraphPad, San Diego, CA, USA). A P-value less than 0.05 was considered statistically significant.
Results
Elevated expression of MLF1IP in CFU-E colonies from PV patients
Previous studies have demonstrated a high level of MLF1IP expression in human bone marrow cells, whereas the mouse homolog has been reported as being confined exclusively to the CFU-E erythroid precursors [6] . To investigate the expression pattern of MLF1IP in human hematopoietic cells, we examined MLF1IP expression in early harvested erythroid colonies (day 7 CFU-E), late-harvested erythroid colonies (day 14 BFU-E), and granulocyte-monocyte colonies (CFU-GM) harvested at the corresponding time using RT-qPCR. The results showed that erythroid colonies exhibited a significantly higher expression of MLF1IP than the corresponding CFU-GM colonies (Fig. 1A) . Because BFU-E and CFU-E are erythroid progenitors characterized by a considerable proliferative capacity during the early stage of erythropoiesis [19] [20] [21] [22] [23] [24] , we speculate that MLF1IP might play an important role during normal erythropoiesis.
Polycythemia vera is an MPN characterized by the excessive generation of red blood cells independent of normal erythropoietic regulation [7, 8] . To investigate the potential association between MLF1IP and PV, we examined MLF1IP transcription in the BMNCs from patients with PV, essential thrombocytosis (ET), primary myelofibrosis (PMF), myelodysplastic syndromes (MDS), or non-M3 acute myeloid leukemia (AML). Among the PV, ET, and PMF patients, all of them had JAK2V617F mutations. No JAK2V617F mutation was found in the CML, AML, and MDS patients. We found that this gene was specifically elevated in PV patients but not in any other disease type (Fig. 1B) . We then collected the CFU-E and BFU-E colonies from the PV patients, ignoring their genotypes, to more precisely demonstrate the stage in which MLF1IP is abnormally expressed. The erythroid colonies from low-risk MDS patients were also added for comparison, which usually represent erythroid hyperplasia in the BM but a decreased peripheral HB value, indicating a dysfunction of erythropoiesis. We found that the MLF1IP level significantly increased in the PV patients in the CFU-E colonies (Fig. 1C) but not BFU-E colonies (Fig. 1D ). Both the CFU-E and BFU-E colonies from the MDS cases showed a markedly reduced MLF1IP expression (Fig. 1C,D) .
Because JAK2V617F is detected in more than 95% of patients diagnosed with PV, we specifically investigated MLF1IP expression in the JAK2V617F-positive PV patients. We observed that MLF1IP expression was significantly induced in the CFU-E cells (Fig. 1E) . In summary, MLF1IP is abundantly expressed in the human CFU-E and BFU-E progenitor cells, but in PV patients, a significant up-regulation of MIL1IP was exclusively detected in the CFU-E colonies, displaying a pathologically specific expression pattern.
MLF1IP promotes cell proliferation by stimulating the cell cycle
To investigate the potential effects of MLF1IP on normal and pathological erythropoiesis, we first assessed its impact on the human erythroleukemic cell line K562 by lentiviral-mediated shRNA knockdown. The RT-qPCR and western blot results confirmed that MLF1IP expression was efficiently down-regulated ( Fig. 2A,B) . We further determined the proliferation of K562 cells after MLF1IP knockdown using CCK-8 assays and clone formation assays and found that the colony number was significantly decreased, suggesting that MLF1IP regulates K562 proliferation ( Fig. 2C-E) . Flow cytometry analyses revealed a significantly increased G0/G1 phase population and a decreased G2/M phase population after MLF1IP knockdown (Fig. 2F,G) . A previous study revealed that the retinoblastoma tumor suppressor gene (RB) is critical for the entry from G1 into the S phase of the cell cycle, while the phosphorylation of RB (pRB), which is initiated by the cell cycle regulatory genes CDKs and D-type cyclins, disrupts RB-mediated cell growth repression [25] . Here, we also discovered that the pRB level was significantly reduced in K562 cells after MLF1IP knockdown (Fig. 2H) , probably resulting from the reduced expression of CDK4, CDK6, cyclin D1, and cyclin D2 (Fig. 2I) . We also found that the cyclin-dependent kinase inhibitors p21 and p27 were up-regulated (Fig. 2J) , which are largely regulated by the ubiquitin-proteasome pathway. Ultimately, the cell cycle was arrested after MLF1IP knockdown.
K562 cells possess the capacity to differentiate into the erythroid lineage when induced by hemin, which is monitored by the appearance of benzidine-positive cells as well as the presence of CD71 +
CD235a
+ cells (Fig. S2A,B) . MLF1IP expression was obviously decreased during erythroid differentiation in K562 cells induced by hemin (Fig. S2C ), which indicated that terminal erythroid differentiation is accompanied by a decreased expression of MLF1IP. However, except for reduced cell proliferation, the knockdown of MLF1IP resulted in neither a morphological abnormality nor a disturbance of erythroid differentiation in these hemininduced erythroid cells (data not shown). To further confirm the hypothesis that MLF1IP expression is down-regulated during terminal erythroid differentiation, we extracted the published RNA-Seq data from the sorted erythroid cells at different differentiated stages which were induced from human cord blood primary CD34
+ cells in vitro [26] . As expected, the MIF1IP was abundantly expressed in the immature erythroblast cells, while its expression was rapidly reduced in the more mature erythroid cells during the differentiation of CD34 + cells toward erythroid lineage (Fig. S2D) . Taken together, MLF1IP promotes cell proliferation by up-regulating cyclin D1, cyclin D2, CDK4, and CDK6 and down-regulating p21 and p27, which ultimately leads to the acceleration of erythroid progenitor cells' entry into the G2/M phase of the cell cycle.
MLF1IP transgenic mice develop a PV-like disorder
Because MLF1IP is significantly up-regulated in CFU-E erythroid progenitor cells in PV patients, we speculated that MLP1IP up-regulation might be involved in the pathogenesis of PV. To validate our hypothesis and investigate the roles of MLF1IP in vivo, we generated MLF1IP Tg mice. Eight transgene-positive founder mice were produced and designated the F0 generation (Fig. 3A) . Across all eight lines of F1 Tg mice, the two most abundantly expressed lines were chosen and termed lines A and B for subsequent studies (Fig. 3B) . Both lines A and B were viable and fertile, but the percentage of Tg progeny of line B was decreased to less than 50% (it should be approximately 75%) for reasons that are currently unknown.
Complete blood counts of the mice were examined at 10-20 weeks. Statistical analyses from the adult F2 mice in both lines revealed that the HB values were significantly increased (line A: 165 AE 5 gÁL À1 ; line B:
174 AE 6 gÁL À1 ) and that there was a corresponding increase in the HCT values from 46 AE 1.5% to The RB protein and phosphorylated RB were measured in empty vector control and MLF1IP knockdown cells by western blot. (I,J) Cell cycle-related molecules were detected by RT-qPCR and western blot after MLF1IP knockdown. GAPDH acted as the reference gene for RTqPCR and the loading control for western blot. Error bars indicate the mean AE SEM. *P < 0.05, **P < 0.01 compared with control.
50 AE 1.5% (line A) and to 53 AE 3.0% (line B) (Fig. 3C) . Additionally, the EPO levels in the plasma were significantly decreased in the Tg mice (Fig. 3D) . These hematological features resemble the typical characteristics of PV. Because PV is usually accompanied by the proliferation of other myeloid lineages, such as thrombocytosis and neutrophilia, we also examined platelets (PLTs), neutrophils, and the white blood cells (WBCs) in these Tg mice. The PLT counts in both Tg mice were increased, but only line A achieved statistical significance. The WBC levels in the Tg mice were also increased, but no changes were detected in the The mean values of HB and EPO represent an inverse correlation in the three groups. The Tg B mice with the highest HB mean value have the lowest EPO level. Plasma samples were obtained from the mice at 10-20 weeks and were analyzed using an ELISA test to determine the mouse EPO levels. Tg A, n = 12; Tg B, n = 6; control, wild-type littermate mice, n = 8. Error bars indicate the mean AE SEM, *P < 0.05, compared with control.
neutrophils (Fig. 3C) , which might indicate that the majority of mouse peripheral WBCs, unlike humans, is composed of lymphocytes, not neutrophils. There was a mild trilineage hypercellularity in the BM and spleen sections of the Tg mice without a marked infiltrate of megakaryocytes or fibrosis (Fig. S3A) , and no significant splenomegaly was observed between the WT and Tg mice during this period (Fig. S3B) . Hematopoietic colony assays were further performed to evaluate the progenitors in the BM from the Tg mice. The frequency of the total colonies produced by the BM cells from the Tg mice was slightly greater than that in the WT controls (data not shown), but the BFU-E and CFU-GEMM from the Tg mice were significantly increased (Fig. 4A ). An increase in number and size of the colonies from the Tg mice was clearly visible when the culture plates with medium were stained with 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (Fig. 4B) . When we scored the colonies under a microscope, larger, faster-maturing, and more HB-synthesized colonies were also observed in the Tg mice (Fig. 4C) . Additionally, we also observed an increase in the number and size of CFU-E colonies from isolated murine c-Kit + cells with MLF1IP overexpression (Fig. S4) . One of the criteria for PV diagnosis was the capability of PV to form erythroid colonies independent of EPO. When culturing Tg mouse BM cells in medium without any cytokines, we unexpectedly observed only tiny cell clusters rather than colonies of a defined type until 10 days after implantation (Fig. 4D) . Therefore, the MLF1IP Tg mice exhibited partial characteristics of PV, such as increased erythroid colonies, HB values, and HCT, and a reduced EPO, but they failed to trigger the pathogenesis of PV alone.
Excessive erythroid expansion is associated with an altered cell cycle status in hematopoietic cells in MLF1IP transgenic mice
To further define the driving forces/stages of erythroid colony proliferation in the Tg mice, flow cytometry was performed to quantify the different populations during hematopoiesis. The Tg mice showed a marked increase in the proportion of LSK + cells, which are enriched for hematopoietic stem cells and multipotent progenitors and megakaryocyte/erythroid progenitor (MEP) cells (Fig. 5A,B) . During erythropoiesis, the E1 population, which contained mostly proerythroblasts and displayed a conspicuously activated state of mitosis, was significantly increased in the Tg mice (Fig. 5C-F) . The E2 and E3 populations, which were composed of more mature erythroblast cells, also represented varying degrees of increase, but the differences were not statistically significant (Fig. 5C-F) .
The cell cycle status of the mouse BM cells was examined by flow cytometry as well. The results showed that more cells in the Tg mice were in the S/ G2/M phases (Fig. 6A,B) . We further detected a higher expression level of cyclin D2 (Fig. 6C) and markedly decreased levels of p21 and p27 in the BM cells (Fig. 6D) . In addition, the Tg mice represented an increased phosphorylated ERK (p-ERK) but a generally normal level of phosphorylated Stat5 (pStat5) (Fig. 6E) . Because previous studies revealed that pStat5 appears very quickly following stimulation [27] [28] [29] [30] , it is possible that we missed the narrow window to capture the changes in pStat5 signals in these Tg mice because MLF1IP was overexpressed from germline stem cells. Therefore, to capture the transient changes of pStat5 signals stimulated by MLF1IP overexpression, we performed an in vitro assay by the transient transduction of MLF1IP into the 293T cell line. After the frequent observation of transfected cells under the fluorescence microscope, we captured the time point at which fluorescence occurred and then examined pStat5 at different time points (0, 30, and 60 min) (Fig. 6F) . The data showed the increased phosphorylation of STAT5 in MLF1IP-transduced cells, indicating that MLF1IP might have an impact on the JAK-STAT pathway.
Taken together, these data demonstrate that elevated MLF1IP alters the expression of pivotal cell cycle regulatory proteins, which results in the increased cell cycling of BM hematopoietic cells.
Discussion
In this study, we report for the first time that MLF1IP expression is exclusively increased in CFU-E cells from PV patients. In vitro K562 cells and subsequent in vivo MLF1IP Tg mouse studies demonstrated that MLF1IP is capable of promoting erythroid cell cycle progression and concomitant proliferation during normal erythropoiesis. Moreover, elevated MLF1IP expression might partially be involved in the pathogenesis of PV.
Tissue-specific expression is often closely related to gene function. Higher MLF1IP expression in erythroid colonies suggests that the MLF1IP gene tends to function in erythropoiesis rather than in other myeloid lineages of the human hematopoietic system. MLF1IP is highly expressed in CFU-E and BFU-E cells from normal BM, which corresponds exactly with their efficient erythropoietic proliferation capacity [31] . Therefore, MLF1IP expression is positively correlated with earlystage erythroblast proliferation.
Our in vitro studies in K562 cells and in vivo studies in hematopoietic cells from MLF1IP Tg mice demonstrated that MLF1IP promotes cell proliferation through cell cycle regulation. In vitro studies revealed that MLF1IP up-regulated cyclin D1, cyclin D2, CDK4, and CDK6 and down-regulated p21 and p27, ultimately leading to an acceleration of erythroid progenitor cells entering the G2/M phase of the cell cycle. These results are consistent with previous studies in chicken DT40 and human HeLa cell lines that showed sample was plated in duplicate. The cells were cultured at 37°C with 5% CO 2 . The hematopoietic colonies were observed on days 4, 7, and 14 and scored on day 10. For visual observation, some of the adequate cell culture wells were entirely stained with a 5 mgÁmL À1 MTT reagent for panel C. The original magnification was 50 9 for panels B and D. CFU-GEMM, colony-forming unit-granulocyte, erythroid, macrophage, megakaryocyte; CFU-GM, sum of colony-forming unit-granulocyte, colony-forming unit-macrophage, and colony-forming unitgranulocyte, macrophage; BFU-E, burst-forming unit-erythroid.
that decreased MLF1IP impairs cell cycle progress and consequently inhibits cell proliferation [3, 4] . In vivo studies also found increased cyclin D2 as well as decreased p27 and p21 in BM cells of MLF1IP Tg mice. It was reported that D-type cyclins couple extracellular signals to activate cell cycle regulators, which trigger the mammalian cell division cycle. The enhancement of any subtype of D-type cyclins, including D1, D2, or D3, shortens the G1-phase and accelerates the G1-S transition [32, 33] . Among all these Dtype cyclins, cyclin D2 is able to more efficiently respond to mitogenic stimulation [34] . Therefore, The proportion of the erythroid cell population (E1, E2, and E3) in the 7-week (E) and 20-week (F) WT (control) or Tg mice BM cells, respectively. Seven-week mice, Control, n = 7; Tg, n = 6. Twenty-week mice, Control, n = 5; Tg, n = 7. Error bars show mean AE SEM, *P < 0.05, **P < 0.01. elevated cyclin D2 confers myeloid progenitors with enhanced proliferative potential and accelerates myeloid reconstitution in hematopoietic cells [35] . Moreover, the overexpression of cyclin D2 can accelerate p27 degradation during the G0-G1 transition, and the deficiency of p27 enlarges the progenitor pool and elevates the proportion of progenitors in the active cycle [36] . The absence of p21 promotes the entry of quiescent hematopoietic stem cells into the division cycle and results in a subsequent increase in cell number [37, 38] . Taken together, we presumed that the dynamic BM proportions of LSK + cells and proerythroblasts in Tg mice resulted from cell cycle activation which included a shortened interphase of mitotic cells and the division of quiescent cells.
Among the classic BCR-ABL-negative MPNs, in addition to PV patients possessing the JAK2V617F mutant, approximately 60% of ET and PMF patients possess this JAK2 mutation as well [39, 40] . Why does the same mutant lead to a diversely lineage-biased disease phenotype? Although the JAK2V617F allele burden is now considered to be critically involved in the phenotypic diversity of classic BCR-ABL-negative MPNs, it is still insufficient to accurately interpret the pathogenesis and progress of PV, ET, and PMF [41] . Therefore, it is more convincing that other molecules are involved in the pathogenesis of JAK2V617F-positive PV, ET, and PMF. Here, we detected that MLF1IP was more highly expressed in PV than that in ET, PMF, and CML, three other classic MPNs. Moreover, overexpression of MLF1IP activates the JAK-STAT signaling via inducing pStat5 in 293T cells. Thus, we presume that in PV patients, MLF1IP acts as the upstream of JAK-STAT pathway by stimulating pSTAT5. Meanwhile, MLF1IP is highly expressed in CFU-E of JAK2V617F-positive PV patients, suggesting that MLF1IP could form a positive feedback loop with JAK-STAT signaling. Taken together, these data suggest that MLF1IP is involved in the pathogenesis of PV. Indeed, we observed a PV-like phenotype in MLF1IP Tg mice, such as an elevated HB value, HCT value, and PLT number but normal neutrophil counts and a subnormal plasma EPO as well as increased erythroid progenitor cells enriched in HB. However, we cannot diagnose these mice as PV because they lack an enlarged spleen, in vitro EEC and typical features of megakaryocytes in their BM biopsies. As sole overexpression of MLF1IP only partially recapitulates the PV phenotype, there should exist additional erythroid-specific molecule(s) cooperated with MLF1IP to induce PV, which is (are) mutated or abnormally expressed. In the near future, we believe that the accumulation of next-generation high-throughput deepsequencing DNA-and RNA-Seq data from JAK2V617F-positive PV patients could identify more currently unknown erythroid-specific genes and shed light on the pathogenesis of PV. These erythroid-specific genes, including MLF1IP, in turn, could serve as the potential biomarker(s) to distinguish PV from ET and PMF with JAK2V617F mutation.
In conclusion, our data demonstrate that MLF1IP promotes erythroid proliferation by regulating the cell cycle status of hematopoietic cells, indicating that the enhanced expression of MLF1IP might be involved in the excessive erythroid expansion of PV.
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